Renewed Growth Cycle Drives a Favorable Sentiment Towards Edwards Lifesciences (EW)

Edwards Lifesciences (NYSE:EW) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds.

On January 20, Adam Maeder from Piper Sandler maintained his Overweight rating on Edwards Lifesciences (NYSE:EW). The analyst also adjusted his price target on the stock from $95 to $98, which now yields almost 20% upside.

Maeder’s revision came after Piper Sandler made adjustments to some of its forecast models, following preliminary fourth-quarter results. These adjustments also incorporate 2026 guidance from the underlying management teams.

Back on January 9, Josh Jennings from TD Cowen upgraded his rating on Edwards Lifesciences (NYSE:EW) from Hold to Buy. The analyst also raised his price target on the stock from $90 to $97, implying 18.5% upside.

Jennings sees a renewed growth cycle the company has entered, driven primarily by the expansion of the transcatheter aortic valve replacement (TAVR) indication. He also attributed his favorable outlook to a strong pipeline of new launches scheduled during the coming year.

Edwards Lifesciences Corporation (NYSE: EW) is a medical technology company that develops patient-focused medical products and technologies to treat critical cardiovascular diseases. It also offers critical care monitoring services along with transcatheter heart valve repair & replacement products. Its surgical structural heart solutions include INSPIRIS aortic surgical valve, INSPIRIS RESILIA aortic valve, KONECT RESILIA, and MITRIS RESILIA valve.

While we acknowledge the potential of EW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This article is originally published at Insider Monkey.